MX393198B - Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones viricas - Google Patents

Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones viricas

Info

Publication number
MX393198B
MX393198B MX2020010949A MX2020010949A MX393198B MX 393198 B MX393198 B MX 393198B MX 2020010949 A MX2020010949 A MX 2020010949A MX 2020010949 A MX2020010949 A MX 2020010949A MX 393198 B MX393198 B MX 393198B
Authority
MX
Mexico
Prior art keywords
prophylaxis
derivatives
novel
treatment
compounds
Prior art date
Application number
MX2020010949A
Other languages
English (en)
Spanish (es)
Other versions
MX2020010949A (es
Inventor
Chungen Liang
Hongying Yun
Jianping Wang
Kun Miao
Xiufang Zheng
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55910966&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX393198(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2020010949A publication Critical patent/MX2020010949A/es
Publication of MX393198B publication Critical patent/MX393198B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2020010949A 2015-05-08 2016-05-04 Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones viricas MX393198B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2015078507 2015-05-08
CN2016078785 2016-04-08
PCT/EP2016/059961 WO2016180695A1 (en) 2015-05-08 2016-05-04 Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection

Publications (2)

Publication Number Publication Date
MX2020010949A MX2020010949A (es) 2022-06-16
MX393198B true MX393198B (es) 2025-03-19

Family

ID=55910966

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020010949A MX393198B (es) 2015-05-08 2016-05-04 Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones viricas
MX2017014033A MX376761B (es) 2015-05-08 2016-05-04 Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2017014033A MX376761B (es) 2015-05-08 2016-05-04 Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas.

Country Status (32)

Country Link
US (3) US9708325B2 (https=)
EP (1) EP3294740B1 (https=)
JP (1) JP6738352B2 (https=)
KR (1) KR102690131B1 (https=)
CN (1) CN107580596B (https=)
AR (1) AR104528A1 (https=)
AU (3) AU2016260683B2 (https=)
BR (1) BR112017023959B1 (https=)
CA (1) CA2982704C (https=)
CL (1) CL2017002745A1 (https=)
CO (1) CO2017009994A2 (https=)
CR (1) CR20170496A (https=)
DK (1) DK3294740T3 (https=)
ES (1) ES2753777T3 (https=)
HR (1) HRP20191942T1 (https=)
HU (1) HUE045906T2 (https=)
IL (2) IL254947B (https=)
LT (1) LT3294740T (https=)
MX (2) MX393198B (https=)
MY (1) MY182353A (https=)
NZ (2) NZ775222A (https=)
PE (1) PE20171620A1 (https=)
PH (1) PH12017502009A1 (https=)
PL (1) PL3294740T3 (https=)
PT (1) PT3294740T (https=)
RS (1) RS59435B1 (https=)
RU (1) RU2745269C2 (https=)
SG (1) SG10202108841YA (https=)
SI (1) SI3294740T1 (https=)
TW (2) TWI706954B (https=)
UA (1) UA120450C2 (https=)
WO (1) WO2016180695A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3294740T3 (pl) 2015-05-08 2020-03-31 F. Hoffmann-La Roche Ag Nowe sulfonoimidoilopurynony i pochodne do leczenia i profilaktyki infekcji wirusowych
PL3504210T3 (pl) * 2016-08-29 2021-07-05 F. Hoffmann-La Roche Ag 7-podstawione związki sulfonimidoilopurynonowe do leczenia i profilaktyki zakażeń wirusowych
EP3512556B1 (en) 2016-09-13 2021-08-18 F. Hoffmann-La Roche AG Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor
JP7328977B2 (ja) 2018-02-12 2023-08-17 エフ． ホフマン－ラ ロシュ アーゲー ウイルス感染の処置および予防のための新規のスルホン化合物および誘導体
JP7089596B2 (ja) * 2018-02-28 2022-06-22 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 肝がんの治療及び予防のための７位置換スルホンイミドイルプリノン化合物及び誘導体
CN111072667A (zh) * 2018-10-22 2020-04-28 罗欣药业(上海)有限公司 五元或六元杂环并嘧啶类化合物及其用途
CA3128081A1 (en) * 2019-02-12 2020-08-20 Ambrx, Inc. Compositions containing, methods and uses of antibody-tlr agonist conjugates
US12503461B2 (en) 2019-09-20 2025-12-23 Syngenta Crop Protection Ag Pesticidally active heterocyclic derivatives with sulfur and sulfoximine containing substituents
WO2021154662A1 (en) * 2020-01-27 2021-08-05 Bristol-Myers Squibb Company 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
EP4097105A1 (en) * 2020-01-27 2022-12-07 Bristol-Myers Squibb Company 1h-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (tlr7) agonists
EP4554678A1 (en) 2022-07-14 2025-05-21 F. Hoffmann-La Roche AG Phosphorylpurinone compounds for the treatment of cancer
CN118724963A (zh) * 2023-03-30 2024-10-01 浙江养生堂天然药物研究所有限公司 含磷或含硫的大环化合物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4189048B2 (ja) * 1997-12-26 2008-12-03 大日本住友製薬株式会社 複素環化合物
AU2006242920A1 (en) * 2005-05-04 2006-11-09 Pfizer Limited 2-amido-6-amino-8-oxopurine derivatives as Toll-Like receptor modulators for the treatment of cancer and viral infections, such as hepatitis C
CN101239980B (zh) 2008-02-18 2011-06-22 靳广毅 免疫受体调节剂偶联体前体和偶联体及其应用
RS53347B (sr) * 2008-12-09 2014-10-31 Gilead Sciences, Inc. Modulatori toll-sličnih receptora
US20110150836A1 (en) 2009-12-22 2011-06-23 Gilead Sciences, Inc. Methods of treating hbv and hcv infection
TWI555737B (zh) * 2011-05-24 2016-11-01 拜耳知識產權公司 含有硫醯亞胺基團之４－芳基－ｎ－苯基－１，３，５－三氮雜苯－２－胺
JP6349256B2 (ja) 2011-11-09 2018-06-27 ヤンセン・サイエンシズ・アイルランド・ユーシー ウイルス感染の治療のためのプリン誘導体
CN110590809B (zh) 2013-03-29 2022-04-19 爱尔兰詹森科学公司 用于治疗病毒感染的大环脱氮-嘌呤酮
HRP20210927T1 (hr) 2014-08-15 2021-09-03 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Spojevi pirolopirimidina koje se koriste kao agonist tlr7
PL3294740T3 (pl) * 2015-05-08 2020-03-31 F. Hoffmann-La Roche Ag Nowe sulfonoimidoilopurynony i pochodne do leczenia i profilaktyki infekcji wirusowych
PL3504210T3 (pl) * 2016-08-29 2021-07-05 F. Hoffmann-La Roche Ag 7-podstawione związki sulfonimidoilopurynonowe do leczenia i profilaktyki zakażeń wirusowych

Also Published As

Publication number Publication date
HUE045906T2 (hu) 2020-01-28
CL2017002745A1 (es) 2018-05-18
BR112017023959A2 (pt) 2018-07-17
TWI768467B (zh) 2022-06-21
US20160326177A1 (en) 2016-11-10
SG10202108841YA (en) 2021-09-29
JP2018515509A (ja) 2018-06-14
HRP20191942T1 (hr) 2020-01-10
NZ775222A (en) 2024-09-27
SI3294740T1 (sl) 2019-12-31
PH12017502009A1 (en) 2018-03-26
AU2020256348B2 (en) 2022-06-16
MX2017014033A (es) 2018-03-01
WO2016180695A1 (en) 2016-11-17
JP6738352B2 (ja) 2020-08-12
BR112017023959B1 (pt) 2023-05-02
RU2017142577A3 (https=) 2019-10-31
CN107580596B (zh) 2020-07-14
ES2753777T3 (es) 2020-04-14
DK3294740T3 (da) 2019-11-04
TWI706954B (zh) 2020-10-11
AR104528A1 (es) 2017-07-26
US20170275286A1 (en) 2017-09-28
IL254947B (en) 2021-02-28
PL3294740T3 (pl) 2020-03-31
US9708325B2 (en) 2017-07-18
NZ735648A (en) 2023-06-30
PT3294740T (pt) 2019-10-29
AU2016260683B2 (en) 2020-10-29
RS59435B1 (sr) 2019-11-29
AU2022204666A1 (en) 2022-07-21
EP3294740A1 (en) 2018-03-21
MX2020010949A (es) 2022-06-16
PE20171620A1 (es) 2017-11-02
HK1247925A1 (zh) 2018-10-05
CA2982704A1 (en) 2016-11-17
KR20180003612A (ko) 2018-01-09
RU2017142577A (ru) 2019-06-10
AU2016260683A1 (en) 2017-10-12
US20200109144A1 (en) 2020-04-09
MX376761B (es) 2025-03-07
US10399983B2 (en) 2019-09-03
IL254947A0 (en) 2017-12-31
MY182353A (en) 2021-01-20
TW201716410A (zh) 2017-05-16
CN107580596A (zh) 2018-01-12
IL280769B2 (en) 2023-07-01
AU2020256348A1 (en) 2020-11-12
KR102690131B1 (ko) 2024-07-31
UA120450C2 (uk) 2019-12-10
CO2017009994A2 (es) 2018-02-20
US11242345B2 (en) 2022-02-08
RU2745269C2 (ru) 2021-03-22
TW202108584A (zh) 2021-03-01
IL280769B1 (en) 2023-03-01
CA2982704C (en) 2023-10-24
CR20170496A (es) 2017-12-05
IL280769A (en) 2021-04-29
EP3294740B1 (en) 2019-09-04
LT3294740T (lt) 2019-11-25

Similar Documents

Publication Publication Date Title
MX2020010949A (es) Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones viricas.
CO2019000932A2 (es) Nuevos compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infección vírica.
CO2017007355A2 (es) Compuestos derivados de pirazincarbozamida y de pirazincarboxilato para el tratamiento de la infección por el virus de hepatitis b
CR20170237A (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales.
MX2023001876A (es) Derivados de rapamicina.
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
UY36170A (es) Compuestos de dihidroisoquinolinona sustituida
MX2017001862A (es) Nuevas piridazonas y triazinonas para el tratamiento y la profilaxis de infeccion por virus de hepatitis b.
CO2018000660A2 (es) Compuestos derivados del (3β)-cholest-5-en-3-alquil-3-ol y (3β)-cholest-3-alquil-3-ol
UY36122A (es) ?derivados de pirrolidina-2,5-diona, composiciones farmacéuticas y métodos para usar como inhibidores ido1?
MX2018005890A (es) Composiciones para tratar atrofia muscular espinal.
DOP2019000140A (es) Compuestos de heterociclo tetracíclicos útiles como inhibidores de la integrasa del vih
MX2016013689A (es) Compuestos 4-amino-imidazoquinolina.
CR20160337A (es) Nuevas heteroarildihidropirimidinas 6-fusionadas para el tratamiento y la profilaxis de la infección por virus de la hepatitis b
CO2019001181A2 (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2
GT201400167A (es) Nuevos derivados de bencil sulfonamida utiles como inhibidores de mogat-2
CL2020002139A1 (es) Compuestos de sulfonimidoilpurinona 7-sustituidos y sus derivados para el tratamiento y prevención del cáncer de hígado.
CO2017009989A2 (es) Piridopirimidinonas y utilización de las mismas como moduladores de receptores de nmda
PY1515461A (es) Derivados de Dihidropirrolopirimidina
CR20160532A (es) Derivados de pirrolidina-2,5-diona, composiciones farmacéuticas y métodos para usar como inhibidores ido1
SV2016005317A (es) Derivados de pirrolidina -2,5-diona, composiciones farmacéuticas y métodos para usar como inhibidores ido1
CO2017003225A2 (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos
ECSP17003149A (es) Compuestos de dihidroisoquinolinona sustituida